Hospital, adult care and long-term care workers had until Monday to get an initial COVID-19 vaccine dose.
Shares of Moderna (NASDAQ: MRNA) are off by 3.4%; Novavax (NASDAQ: NVAX) is down 5.1%; and Ocugen's (NASDAQ: OCGN) stock is in the red by a jaw-dropping 13.3%, all as of 3:34 p.m. EDT Friday. The U.S. Food and Drug Administration (FDA) might delay the decision on Moderna's jab for adolescents due to safety issues, according to a report from the Wall Street Journal.
Authorization for Moderna's (MRNA) COVID-19 vaccine for ages 12-17 was put on hold Friday in light of concerns over a rare side effect known as myocarditis, or a heart inflammation.
There’s a new biotech in town flying under the Street’s radar. Jasper Therapeutics (JSPR) only went public in September via the SPAC route, and the stock still has a low profile on Wall Street. One analyst, however, has been taking notes, and he is decidedly positive. “We view JSPR as an emerging leader in the development of novel targeted conditioning agents for hematopoietic stem cell transplantation (HSCT) with lead candidate JSP191 and proprietary engineered hematopoietic stem cell (eHSC) pl
The company said the FDA pointed to "deficiencies" related to the regulator's inspection of Revance's manufacturing site. No other concerns were raised in the agency's "complete response letter", the drug developer said. Revance's DaxibotulinumtoxinA for Injection, a potential rival for AbbVie Inc's Botox anti-wrinkle injection, was successful in reducing moderate to severe frown lines in a late-stage study in December 2018.
Spouses can't claim benefits before the higher-earning spouse has claimed, financial expert says
What happened Shares of Moderna (NASDAQ: MRNA) were falling 3.3% as of 3:34 p.m. EDT on Friday. The decline came after The Wall Street Journal reported that the U.S. Food and Drug Administration is delaying a decision on Emergency Use Authorization for Moderna's COVID-19 vaccine in adolescents ages 12 through 17.
The delta variant's grip on the country has created a gargantuan challenge for companies working on desperately needed treatments, and for Covid stocks.
Shares of Merck & Co. Inc. were down 0.1% in premarket trading on Friday, the day after the Food and Drug Administration said it plans to convene an advisory committee on Nov. 30 to discuss the company's experimental COVID-19 pill, molnupiravir. Merck is developing the antiviral with the privately held Ridgeback Biotherapeutics; it recently applied for emergency authorization. The FDA requested advisory committee meetings for each of the authorized COVID-19 vaccines but it did not convene one ah
401(k) money doesn't affect the amount of your Social Security benefits, but it can affect whether they're subject to income tax.
The pandemic has changed attitudes and priorities around work, and there are signs that many have moved on to an alternate economy, writes Lisa Beilfuss.
Moderna stock dipped Friday on a report the FDA is delaying its review of the company's Covid vaccine in teens.
MeiraGtx is quietly working on a promising new approach to gene therapy. Sizing up the opportunity, pondering the unknowns.
Trial results from Merck’s oral Covid-19 antiviral dented the stocks of other biopharma firms that sell monoclonal antibody treatments for the disease.
Despite the recent progress, health officials warn Americans should brace for another wave this winter.
For more risk-tolerant investors, biotechs are screaming buys. This space is consistently on the Street’s radar as a single catalyst such as a positive FDA outcome or promising trial results can send shares through the roof. For example, last week ChemoCentryx (CCXI) saw its share prices skyrocket 100% in just one day, after the FDA approved its blood vessel inflammation drug Tavneos. However, the reverse also holds true meaning that biotech stocks carry their fair share of risk. So how are inve
The number of Americans applying for first-time jobless claims reached its lowest since March 2020 last week, with the number of filings coming in at a better-than-expected 293,000.
If you're concerned that the U.S. government wants to monitor your bank account, you're not alone. Plenty of lawmakers, consumers and banking trade groups are pushing back against the idea, which was...
The Old-Age, Survivors and Disability Insurance program (OASDI) tax—more commonly called the Social Security tax—is calculated by taking a set percentage of your income from each paycheck. For both 2021 and 2022, the Social Security tax rate for employees and employers is 6.2% of employee compensation, for a total of 12.4%. The combined taxes withheld for Social Security and Medicare are referred to as the Federal Insurance Contributions Act (FICA).
President Biden has discussed the latest trends in retail fuel prices with representatives of the U.S. oil industry
The former Trump White House press secretary earned a blistering two-word rebuke from Mary Trump, the ex-president's niece.